All In Biotech

NDA 213690 · Journey

Zilxi

Minocycline Hydrochloride · Topical

Last checked: Nov 20, 2026Latest source record: Feb 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

May 28, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

291

55 Phase 3, 18 recruiting

FAERS reports

11,615

8,929 serious, 1,645 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 9, 2024.

ZILXI is indicated for the treatment of inflammatory lesions of rosacea in adults [see Clinical Studies ( 14 )] . Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ZILXI should be used only as indicated [see Warnings and Precautions ( 5.14 )] . ZILXI is a tetracycline-class drug indicated for the treatment of inflammatory lesions of rosacea in adults. ( 1 ) Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ZILXI should be used only as indicated ( 1 ).

Mechanism: The mechanism of action of ZILXI for the treatment of inflammatory lesions of rosacea is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 28, 2020 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • ZILXI · MINOCYCLINE HYDROCHLORIDE EQ 1.5% BASE · AEROSOL, FOAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Minocycline" as an intervention, any sponsor and status, largest first.

All 291 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,974
  • off label use1,482
  • nausea1,075
  • pain1,019
  • arthralgia1,001
  • fatigue957
  • drug intolerance913
  • rash909
  • drug hypersensitivity908
  • rheumatoid arthritis879
  • joint swelling873
  • headache802

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200411
200552
20067
20072
20086
200979
201086
201199
2012233
2013416
2014431
2015539
2016806
2017871
2018894
20191,143
20201,001
2021762
2022695
2023877
20241,202
2025966
2026437

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zilxi (Minocycline HCl)

2024 spending

$430K

Beneficiaries

462

901 claims

Per beneficiary

$931

$15.50 per unit

View as table
YearSpending
2020$21,424
2021$325,070
2022$371,793
2023$402,571
2024$430,122

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 690 on PubMed

Sponsor: Journey

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.